性交疼痛治療の世界市場：薬剤タイプ別、投与経路別、流通チャネル別、地域別

世界の性交疼痛治療の市場規模は、2024年に7億5,410万米ドルに達し、2024～2031年にかけてCAGR 4.6%で成長し、2031年には10億3,540万米ドルに達すると予測されています。

図.性交疼痛治療市場シェア（%）、2024年地域別

性交痛（性交困難症）は、世界的に女性に蔓延している問題です。これは、挿入中または挿入後の骨盤領域またはその周辺の痛みを特徴とし、身体的および心理的な影響を及ぼします。正確な原因は人によって異なりますが、一般的な原因としては、膣感染症、子宮内膜症、心理的要因、出産時の骨盤周辺の損傷などが挙げられます。治療せずに放置すると、生活の質や性的関係に悪影響を及ぼす可能性があります。性交障害治療市場は、痛みを和らげ、親密さを回復させる医薬品や医療機器の選択肢で構成されています。ホルモン療法、理学療法、低侵襲手術などの治療分野の進歩により、この症状を効果的に管理する選択肢が広がっています。

市場力学：

利用可能な治療選択肢に関する意識の高まりと、女性のセクシュアリティに関するよりオープンな議論が、性交疼痛治療市場を牽引しています。女性の健康問題にまつわる歴史的なスティグマは、患者が治療を求める力が強まったと感じるにつれて徐々に減少しています。薬理学的管理に代わる非侵襲的かつ非薬物的な選択肢に対する需要の高まりが、この分野における理学療法ツールや医療機器のチャンスを広げています。しかし、新しい技術に伴う高コストは、市場の拡大をある程度制限する可能性があります。地域によっては、文化的・社会的障壁が助けを求める行動を妨げ続けています。一方、骨盤底障害や神経学的問題を抱える高齢化社会は、市場参入企業に新たな展望をもたらします。

本調査の主な特徴

• 本レポートでは、世界の性交疼痛治療市場を詳細に分析し、2023年を基準年とした予測期間（2024～2031年）の市場規模（100万米ドル）および複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場に対する魅力的な投資提案マトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業のハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の性交障害治療市場の主要企業をプロファイルしています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の性交疼痛治療市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界の性交疼痛治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 最近の動向
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• 払い戻しシナリオ
• PEST分析
• ポーターの分析

第4章 世界の性交疼痛治療市場 - COVID-19パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の性交疼痛治療市場、薬剤タイプ別、2019～2031年（100万米ドル）

• 選択的エストロゲン受容体モジュレーター
• エストロゲン（その他の膣剤）
• コルチコステロイド
• 抗生物質
• その他

第6章 世界の性交疼痛治療市場、投与経路別、2019～2031年（100万米ドル）

• 経口
• 膣挿インサート
• その他

第7章 世界の性交疼痛治療市場、流通チャネル別、2019～2031年（100万米ドル）

• 小売薬局
• 病院薬局
• eコマース
• その他

第8章 世界の性交疼痛治療市場、地域別、2019～2031年（100万米ドル）

第9章 競合情勢

• 企業プロファイル
  • Lupin
  • Pfizer Inc.
  • AbbVie Inc.
  • Duchesnay Inc.
  • AMAG Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals LLC.
  • TherapeuticsMD, Inc.
  • Sumitomo Pharma Co., Ltd.,
  • Myovant Sciences
  • Novo Nordisk A/S
  • Viatris Inc.
  • Shionogi & Co., Ltd.
  • Millicent Pharma Ltd.
  • Cosette Pharmaceuticals, Inc.
  • Mundipharma International

第10章 アナリストの視点

第11章 参考文献と調査手法

The dyspareunia treatment market is estimated to be valued at USD 754.1 Mn in 2024 and is expected to reach USD 1,035.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.

Figure. Dyspareunia Treatment Market Share (%), By Region 2024

Dyspareunia, or painful sexual intercourse, is a prevalent issue that affects women globally. It is characterized by pain in the pelvic region or surrounding area during or after penetration, and has physical as well as psychological implications. The exact causes may vary from person to person, but common contributors include vaginal infections, endometriosis, psychological factors, and pelvic area injuries during childbirth. If left untreated, it can have a negative impact on quality of life and sexual relationships. The dyspareunia treatment market consists of pharmaceutical and medical device options that provide relief from pain and help restore intimacy. Advancements in therapeutic areas like hormonal therapy, physical therapy, and minimally invasive procedures are expanding choices for managing this condition effectively.

Market Dynamics:

Rising awareness about available treatment choices and more open discussion of female sexuality are driving the dyspareunia treatment market. Historical stigma around women's health issues is gradually reducing as patients feel more empowered to seek care. Growing demand for non-invasive and non-drug alternatives to pharmacological management is opening up opportunities for physical therapy tools and medical devices in this space. However, high costs associated with newer technologies could restrict market expansion to some degree. Cultural and social barriers continue to hamper help-seeking behavior in certain regions as well. Meanwhile, an aging population presenting with pelvic floor disorders and neurological issues presents new prospects for market participants.

Key Features of the Study:

• This report provides an in-depth analysis of the global dyspareunia treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global dyspareunia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study includes Lupin, Pfizer Inc., AbbVie Inc., Duchesnay Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., TherapeuticsMD, Inc., Sumitomo Pharma Co., Ltd., Myovant Sciences, Novo Nordisk A/S, Viatris Inc., Shionogi & Co., Ltd., Millicent Pharma Ltd., Cosette Pharmaceuticals, Inc., and Mundipharma International
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global dyspareunia treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dyspareunia treatment market

Detailed Segmentation-

• Drug Type:
  • Selective Estrogen Receptor Modulators
  • Estrogens (Miscellaneous Vaginal Agents)
  • Corticosteroids
  • Antibiotics
  • Others
• Route of Administration:
  • Oral
  • Vaginal Inserts
  • Others
• Distribution Channel:
  • Retail Pharmacies
  • Hospital Pharmacies
  • E-Commerce
  • Others
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Lupin
  • Pfizer Inc.
  • AbbVie Inc.
  • Duchesnay Inc.
  • AMAG Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals LLC.
  • TherapeuticsMD, Inc.
  • Sumitomo Pharma Co., Ltd.,
  • Myovant Sciences
  • Novo Nordisk A/S
  • Viatris Inc.
  • Shionogi & Co., Ltd.
  • Millicent Pharma Ltd.
  • Cosette Pharmaceuticals, Inc.
  • Mundipharma International

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Fundings and Investments
• Reimbursement Scenario
• PEST Analysis
• Porter's Analysis

4. Global Dyspareunia Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Dyspareunia Treatment Market, By Drug Type, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Selective Estrogen Receptor Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Estrogens (Miscellaneous Vaginal Agents)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Dyspareunia Treatment Market, By Route of Administration, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Vaginal Inserts
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Dyspareunia Treatment Market, By Distribution Channel, 2019 - 2031, (USD Mn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• E-commerce
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Dyspareunia Treatment Market, By Region, 2019 - 2031, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.S.
    • Canada
    • Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
    • Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Lupin*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Duchesnay Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AMAG Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amneal Pharmaceuticals LLC.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • TherapeuticsMD, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sumitomo Pharma Co., Ltd.,
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Myovant Sciences
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Shionogi & Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Millicent Pharma Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Cosette Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mundipharma International
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Analyst View

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact